Empliciti
Empliciti ingredients
| Active ingredient | Strength |
|---|---|
| Elotuzumab | 300 mg/1, 400 mg/1 |
What Empliciti is used for
The FDA lists the approved uses on the official label (below). In the EU, elotuzumab is approved as Empliciti for:
Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Empliciti
- Generic name
- Elotuzumab
- Made by
- E.R. Squibb & Sons, L.L.C.
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- Drug class
- SLAMF7-directed Immunostimulatory Antibody
- FDA approval
- Biologic licence (BLA) BLA761035
- On the US market since
- 2015
Official information
- Empliciti prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Elotuzumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Empliciti?
Empliciti (Elotuzumab) is a cancer medicine made by E.R. Squibb & Sons, L.L.C., approved by the US FDA.
What are the ingredients of Empliciti?
Empliciti contains Elotuzumab (300 mg/1, 400 mg/1).
Is Empliciti approved in Europe?
The same active substance is approved in the EU as Empliciti.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA